Sangrix annual ebitda
2017
2018
2019
2022
2023
2024
2025
Sangrix EBITDA Growth & History (SGRX)
Sangrix's calculated EBITDA was −$3.0M for fiscal 2025.
View full Sangrix company overviewSangrix annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-06-30 | −$3.0M | $10.9M | — |
| 2024 | 2024-06-30 | −$13.9M | $9.0M | — |
| 2023 | 2023-06-30 | −$22.9M | −$17.9M | — |
| 2022 | 2022-06-30 | −$5.0M | — | — |
| 2019 | 2019-06-30 | $178,323 | −$7.4M | −97.65% |
| 2018 | 2018-06-30 | $7.6M | $3.5M | +87.13% |
| 2017 | 2017-06-30 | $4.1M | — | — |
Sangrix ebitda trends
Between the periods ended 2017-06-30 and 2025-06-30, Sangrix's ebitda decreased from $4.1M to −$3.0M, a change of −$7.0M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Sangrix source filings ↗